Status:
COMPLETED
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
10-17 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe and the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentr...
Eligibility Criteria
Inclusion
- BMI greater than 85th percentile for age and gender
- Currently being treated with diet and exercise or metformin alone
- HbA1c (glycosylated haemoglobin) between 6.5 and 11.0%
Exclusion
- Any clinically significant disease other than type 2 diabetes, as judged by the trial physician
- Previous treatment with any anti-diabetic drug other than metformin (except for prior short term treatment, at the discretion of the trial physician)
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00943501
Start Date
November 1 2009
End Date
September 1 2011
Last Update
January 26 2017
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Cypress, California, United States, 90630
2
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90036
3
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90048-1869
4
Novo Nordisk Investigational Site
Aurora, Colorado, United States, 80045